Schizophrenia Battery
|
|
- Everett Shelton
- 5 years ago
- Views:
Transcription
1 Schizophrenia Battery
2 Cantab Schizophrenia Battery A c c e l e r a t e t h e d e v e l o p m e n t o f s a f e a n d e f f e c t i v e m e d i c i n e s Fast, reliable and highly sensitive, the Cantab Schizophrenia Battery allows accurate quantification of cognitive effects when testing investigational drugs for Schizophrenia. Motor and mental response speed Visual learning and memory Planning Executive function Recognition memory Reaction Time (RTI) Paired Associates Learning (PAL) Stockings of Cambridge (OTS) Verbal Recognition Memory (VRM) Attention / reaction time Mnemonic Executive function Cognitive flexibility Emotional processing Rapid Visual Information Processing (RVP) Spatial Working Memory (SWM) Intra/Extra- Dimensional Shift (IED) Emotional Recognition Task (ERT)
3 Percent passing each stage (IED) Sensitive to cognitive impairment in schizophrenia and its prodrome Maximize scope for detecting cognitive benefits of intervention, and enrich samples, with large baseline deficits in schizophrenia Graded task difficulty enables robust detection of cognitive impairment even in first-episode of schizophreniform illness 2 Planning Executive Function (OTS) significant clinical impairment First episode schizophrenia Healthy Controls Mnemonic Executive Function (SWM) greater impairment greater impairment 75 Associative learning (PAL) Impairment (Z-Score) vs Controls 70 Task stage increasing task difficulty IED impairment also correlates with duration of untreated illness (p=0.0) 2 Calculated from Hutton et al., Psych Med, 998; see also Aleman et al., Am J Psych, 999 & Liu et al., Schiz Res, 20;. 2 Joyce et al., B J Psych, 2002; see also Barnett et al., Neurosci Biobeh Rev, 200.
4 Composite CANTAB Score Objective measures that are clinically relevant and superior to alternative tests CANTAB predicts day-to-day function in schizophrenia better CANTAB Schizophrenia performance Highly significant correlation between CANTAB and everyday functioning (p<0.00) better everyday function CANTAB also predicts subjective cognitive complaints, quality of life, community functioning, and extent of negative symptoms, in schizophrenia 2 Everyday functioning (UPSA-2 total score) Baker et al., poster at International Society for CNS Trials and Methodology, e.g. Prouteau et al., Schiz Res, 2004; Prouteau et al., Psych Res, 2004; Zhornitsky et al., 203; Saleem et al., J Psychopharm, 204. UPSA = University of California San Diego Performance-based Skills Assessment
5 PAL errors Firm scientific grounding for hypothesis testing and dissemination of results Front of brain CANTAB OTS test is sensitive to frontal lobe dysfunction in schizophrenia Healthy Volunteer Normal frontal activation as expected (red) CANTAB PAL test impairment correlates with hippocampus volume loss in schizophrenia (p=0.00) 2 30 worse PAL performance Front of brain At rest During OTS Schizophrenia Failure of frontal activation 20 smaller hippocampus Hippocampus volume in schizophrenia (mm 3 ) At rest During OTS Andreasen et al., Arch Gen Psych, Keri et al., Neuropsychologia, 202
6 Sustained attention (RVP) Enhanced early decision -making using cognition as a biomarker CASE STUDY Pro-cognitive effect of tropisetron (alpha-7 nicotinic acetylcholine receptor partial agonist / 5- HT3 antagonist) following 8-week treatment in just N=2 patients with schizophrenia (nonsmokers). Clinical measures were insensitive with this small N * p < 0.00 improvement Beneficial effects of tropisetron on symptoms of Schizophrenia were identified in a larger subsequent clinical trial 2 Baseline 8-weeks Shiina et al., Ann Gen Psych, 200; 2 Noroozian et al., Psychopharm, 203
7 Errors (SWM) Errors (PAL) Detect procognitive effects of treatment and make informed dose selection decisions CASE STUDY Cognitive improvement versus placebo following 22-week minocycline augmentation (antiinflammatory/anti-microbial) in Schizophrenia (N=54) CASE STUDY Selective cognitive improvement following 4-week SAM-53 treatment (5-HT6 antagonism) at 3mg/day in prototypical cognitive disorder (Alzheimer s Disease, N=74) * p < 0.05 Week -2 Week 0 Week 22 Minocycline + atypical antipsychotics Placebo + atypical antipsychotics better performance * p < 0.05 Improvement Placebo 0.5mg.5mg 3mg 5mg Deterioration CANTAB PAL Levkovitz et al., J Clin Psych, Brisard et al., ICAD conference, 200
8 Change in PAL total errors adjusted Early and sensitive detection of safety signals, including effects not predicted by animal models CASE STUDY: Contrary to expectations from animal models, acute treatment with higher dose alpha-5ia (GABA-A receptor subtype inverse agonist) impaired PAL in healthy volunteers (Phase efficacy study) CASE STUDY: CANTAB detects unwanted synergistic interactions between schizophrenia-relevant compounds, and can highlight equivalence (such as to blood alcohol concentrations [BAC]) * p < 0.05 Deterioration equivalent to BAC>0.% Deterioration Placebo 2mg 4mg equivalent to BAC>0.05% Atack, Pharmacol Ther, Internal Camcog data
9 Cantab Solutions The world s leading cognitive assessments Schizophrenia Battery Touchscreen assessment system for smaller, faster, more accurate trials Sensitive to cognitive impairment even at early stages of the disorder Detects efficacy signals where other measures fail Early and sensitive detection of safety signals Enhances decision-making in clinical trials using cognition as a biomarker
10 Chicago 225 York Road, Suite 20 Oak Brook Illinois, USA Tel: Cambridge Tunbridge Court Bottisham Cambridge, CB25 9TU UK Tel: Contact clinicaltrials@camcog.com Visit Cambridge Cognition 204. All rights reserved. CTIS Schizophrenia v..4.4
Adaptive Design in CIAS
Adaptive Design in CIAS or If you don t know where you re going, any road will get you there Michael Sand, PhD, MPH Senior Clinical Program Leader, CNS Boehringer Ingelheim Disclosures I m an employee
More informationCANTAB Test descriptions by function
CANTAB Test descriptions by function The 22 tests in the CANTAB battery may be divided into the following main types of task: screening tests visual memory tests executive function, working memory and
More informationCognitive Testing on Mobile & Wearable Devices
Cognitive Testing on Mobile & Wearable Devices Krystyna Zaluski CANTAB Connect Prodromal Alzheimer s Background Cambridge Cognition 2016. All rights reserved Page 1 Overview A neuroscience digital health
More informationCTIS-Adverse Effects
White Paper CTIS-Adverse Effects A new Clinical Trial Information System for assessing cognitive safety in Phase I drug trials Dr Andrew Blackwell, Chief Scientific Officer, Cambridge Cognition 2 CTIS-Adverse
More informationCognitive Health in the Workplace
Mild Cognitive Impairment: Uncovering the Impact on an Ageing Workforce Cognitive Health in the Workplace Dr Jenny Barnett Director, Healthcare Innovation CANTAB Corporate Health Validated by 30 years
More informationAssessing cognitive safety and tolerability in drug trials
1 Assessing cognitive safety and tolerability in drug trials Dr Charlotte Housden, Cambridge Cognition 2 There is increasing pressure on pharmaceutical companies to accelerate the development of safe and
More informationESSENTIAL PSYCHOPHARMACOLOGY, Neurobiology of Schizophrenia Carl Salzman MD Montreal
ESSENTIAL PSYCHOPHARMACOLOGY, 2011 Neurobiology of Schizophrenia Carl Salzman MD Montreal EVOLVING CONCEPTS OF SCHIZOPHRENIA Psychotic illness with delusions, hallucinations, thought disorder and deterioration;
More informationComputerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB
Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB Marie-Noëlle Levaux a,c, Stéphane Potvin a,d, Amir Ali Sepehry a,b,d, Juliette Sablier a,d, Adrianna Mendrek a,b,
More informationEffects of acute ketamine infusion on visual working memory encoding: a study using ERPs
Effects of acute ketamine infusion on visual working memory encoding: a study using ERPs Corinna Haenschel Psychology, City University London, UK Partly Funded by: the Welsh Institute of Cognitive Neuroscience
More informationNeuropsychology of Attention Deficit Hyperactivity Disorder (ADHD)
Neuropsychology of Attention Deficit Hyperactivity Disorder (ADHD) Ronna Fried, Ed.D. Director of Neuropsychology Clinical & Research Programs in Pediatric Psychopharmacology and Adult ADHD Massachusetts
More informationADHD in children and adolescents: examination of the association of neurological subtle signs with working memory problems
ADHD in children and adolescents: examination of the association of neurological subtle signs with working memory problems Winther, J., Aggarwal, S., Hall, N, Rennie, K., C Prakash, Williams, J., & Vance,
More informationBiomarkers in Schizophrenia
Biomarkers in Schizophrenia David A. Lewis, MD Translational Neuroscience Program Department of Psychiatry NIMH Conte Center for the Neuroscience of Mental Disorders University of Pittsburgh Disease Process
More informationPharmacological treatments for ASD
Behavioural and Developmental Psychiatry Clinical Academic Group (CAG) 18 June 2015 Pharmacological treatments for ASD Dr Grainne McAlonan Head of Research BDP CAG, King s Health Partners Reader (Clinical),
More informationPERCEPTION: Gain Control & Integration. Mark A. Geyer, Ph.D. Departments of Psychiatry & Neurosciences University of California, San Diego
PERCEPTION: Gain Control & Integration Mark A. Geyer, Ph.D. Departments of Psychiatry & Neurosciences University of California, San Diego Perception Integration Integration: The processes linking the output
More informationThis is Your Brain after the Drugs: Neural Functioning in Adolescent Substance Users. Susan F. Tapert, Ph.D. University of California, San Diego
This is Your Brain after the Drugs: Neural Functioning in Adolescent Substance Users Susan F. Tapert, Ph.D. University of California, San Diego Overview What is normal adolescence? Does substance use affect
More informationEarly intervention in Bipolar Disorder
Early intervention in Bipolar Disorder Lakshmi N. Yatham MBBS, FRCPC, MRCPsych Professor of Psychiatry, University of British Columbia, Vancouver, Canada Early Intervention in Bipolar Disorder High Risk
More informationResearch Funding & Grant Application Guide for neuroscience, psychiatry & psychology
Research Funding & Grant Application Guide for neuroscience, psychiatry & psychology 2 Cantab Ignition Bright resources to spark brilliant research Cantab Ignition is a collection of free educational resources
More informationNeurocognitive Graphs of Schizophrenia and Major Depression Based on Cognitive Features
Supplementary Materials Neurocognitive Graphs of Schizophrenia and Major Depression Based on Cognitive Features Sugai Liang#, Roberto Vega#, Xiangzhen Kong, Wei Deng, Qiang Wang, Xiaohong Ma, Mingli Li,
More informationCognitive enhancement therapy in schizophrenia. Matcheri S Keshavan MD
Cognitive enhancement therapy in schizophrenia Matcheri S Keshavan MD Harvard Medical School, Massachusetts Mental Health Center and Beth Israel Deaconess Medical Center NIMH MH 60902, 92440 and 105596;
More informationIndex. Index. More information
ability dysfunctional beliefs affecting 91 92 motivation and negative symptoms 90 91 acetylcholine 269 270 acetylcholinesterase inhibitors 272 adolescents, relevance of performance-based measures 262 affect
More informationIdentifying Youth at Clinical High Risk for Psychosis
Identifying Youth at Clinical High Risk for Psychosis Jean Addington PhD University of Calgary Department of Psychiatry 1 Identifying Youth at Clinical High Risk for Psychosis Part 1: What do we know about
More informationSmart drugs : Brain actions and ethical issues
Smart drugs : Brain actions and ethical issues Professor Barbara J Sahakian FMedSci President of the British Association for Psychopharmacology President of the International Neuroethics Society University
More informationCurriculum Vitae, Corinna A. Gamez, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationOpen Translational Science in Schizophrenia. Harvard Catalyst Workshop March 24, 2015
Open Translational Science in Schizophrenia Harvard Catalyst Workshop March 24, 2015 1 Fostering Use of the Janssen Clinical Trial Data The goal of this project is to foster collaborations around Janssen
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationCOGNITIVE AND BRAIN CHANGES IN MULTIPLE SCLEROSIS
1 COGNITIVE AND BRAIN CHANGES IN MULTIPLE SCLEROSIS MARCH 27, 2017 Esther Fujiwara, Ph.D. (efujiwara@ualberta.ca) Department of Psychiatry, University of Alberta 2 Objectives 1. Identify cognitive challenges
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Schizophrenia and Cognition Jeffrey A. Lieberman, MD Columbia University College of Physicians and Surgeons New York State Psychiatric
More informationPsychology 320: Topics in Physiological Psychology Lecture Exam 2: March 19th, 2003
Psychology 320: Topics in Physiological Psychology Lecture Exam 2: March 19th, 2003 Name: Student #: BEFORE YOU BEGIN!!! 1) Count the number of pages in your exam. The exam is 8 pages long; if you do not
More informationEpilepsy and Neuropsychology
Epilepsy and Neuropsychology Dr. Sare Akdag, RPsych Neuropsychology Service, BC Children s Hospital Clinical Assistant Professor, Dept of Paediatrics, UBC November 24, 2008 BC Epilepsy Society Lecture
More informationBrief Report. Does Modafinil Enhance Cognitive Performance in Young Volunteers Who Are Not Sleep-Deprived?
Brief Report Does Modafinil Enhance Cognitive Performance in Young Volunteers Who Are Not Sleep-Deprived? Delia C. Randall, BSc,*y Aparna Viswanath,* Punam Bharania,* Sarah M. Elsabagh, BSc,* David E.
More informationSensory Gating Measures. Auditory P50 Response Prepulse Inhibition of Startle (PPI) Bruce Turetsky, M.D. IOM Workshop June 22, 2010
Sensory Gating Measures Auditory P50 Response Prepulse Inhibition of Startle (PPI) Bruce Turetsky, M.D. IOM Workshop June 22, 2010 Heuristically, sensory gating denotes the ability to filter out irrelevant
More informationCONDUCTING THE RIGHT PROOF OF CONCEPT STUDY. Michael F. Egan, MD Clinical Neuroscience, Merck
CONDUCTING THE RIGHT PROOF OF CONCEPT STUDY Michael F. Egan, MD Clinical Neuroscience, Merck Introduction Drugs for some CNS targets (e.g. alpha7, PDE10, glutamate targets, muscarinic M1/M4 agonist, etc)
More informationNeuropsychology of Attention Deficit Hyperactivity Disorder (ADHD)
Neuropsychology of Attention Deficit Hyperactivity Disorder (ADHD) Ronna Fried, Ed.D. Director of Neuropsychology in the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts
More informationPsychotic Disorders. Schizophrenia. Age Distribution of Onset 2/24/2009. Schizophrenia. Hallmark trait is psychosis
Psychotic Disorders Schizophrenia Schizophrenia Affects people from all walks of life Is about as prevalent as epilepsy Usually begins in late adolescence or early adulthood Hallmark trait is psychosis
More informationCantab Mobile. A Scientific and Clinical Review
Cantab Mobile A Scientific and Clinical Review Contents Scientific background 4 Sensitive to Alzheimer's disease and mild cognitive impairment 4 Performance linked to brain regions first affected in Alzheimer's
More informationΔTHC level. ΔTHC-COOH level
Supplemental information 12 2 11 18 1 16 THC (ng/dl) A 9 8 7 6 5 4 3 2 1 5 1 15 2 Minutes 25 ΔTHC level B 14 12 1 8 6 4 2-2 -4 y = 11.92x + 42.11 R² =.1375 y =.196x + 29.63 R² =.2977 y =.1513x +.8471 R²
More informationHalle R. Dimsdale-Zucker 1544 Newton Court UC Davis Center for Neuroscience Davis, CA Address:
Halle R. Dimsdale-Zucker 1544 Newton Court UC Davis Center for Neuroscience Davis, CA 95618 E-Mail Address: hrzucker@ucdavis.edu Education 2013-current Ph.D. in Cognitive Neuroscience Advanced to Candidacy,
More informationWhat Can the Brain Teach Us About Treating PTSD? Thomas C. Neylan, MD Norbert Schuff, PhD Charles R. Marmar, MD Michael W.
What Can the Brain Teach Us About Treating PTSD? Thomas C. Neylan, MD Norbert Schuff, PhD Charles R. Marmar, MD Michael W. Weiner, MD Stress and Biological Sciences Abram Kardiner (1891-1981) Described
More informationChapter 2. An Integrative Approach to Psychopathology
Page 1 Chapter 2 An Integrative Approach to Psychopathology One-Dimensional vs. Multidimensional Models One-Dimensional Models Could mean a paradigm, school, or conceptual approach Could mean an emphasis
More informationImproving the Methodology for Assessing Mild Cognitive Impairment Across the Lifespan
Improving the Methodology for Assessing Mild Cognitive Impairment Across the Lifespan Grant L. Iverson, Ph.D, Professor Department of Physical Medicine and Rehabilitation Harvard Medical School & Red Sox
More informationBiological Risk Factors
Biological Risk Factors Ms Angelina Crea Provisional Psychologist Academic Child Psychiatry Unit Royal Children s Hospital Professor Alasdair Vance Head Academic Child Psychiatry Department of Paediatrics
More informationDeep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: a feasibility study
International Journal of Neuropsychopharmacology (2011), 14, 991 996. f CINP 2011 doi:10.1017/s1461145711000642 Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive
More informationMirror Neurons in Primates, Humans, and Implications for Neuropsychiatric Disorders
Mirror Neurons in Primates, Humans, and Implications for Neuropsychiatric Disorders Fiza Singh, M.D. H.S. Assistant Clinical Professor of Psychiatry UCSD School of Medicine VA San Diego Healthcare System
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationCurriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationClinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?
Schizophrenia Bulletin vol. 39 no. 2 pp. 417 435, 2013 doi:10.1093/schbul/sbr153 Advance Access publication November 22, 2011 Clinical Trials of Potential -Enhancing Drugs in Schizophrenia: What Have We
More informationCurriculum Vitae, David P. Walling, Ph.D. David P. Walling, Ph.D. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationAre Two Antipsychotics Better Than One?
Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationDisease Modification in Schizophrenia: Overview of the Issues. ISCTM February 18 th 2014 Ravi Anand, MD Switzerland
Disease Modification in Schizophrenia: Overview of the Issues ISCTM February 18 th 2014 Ravi Anand, MD Switzerland Need for a New Treatment Paradigm in Schizophrenia Sixty years after approval for the
More informationNicotinic Agonists for Cognitive Deficits in Schizophrenia: A Case Report
Nicotinic Agonists for Cognitive Deficits in Schizophrenia: A Case Report Annette Kennedy, PsyD Seattle Inst of Biomedical & Clinical Research, Mental Illness Research Education & Clinical Center (MIRECC)
More informationThe outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry
The outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry Robin M Murray Department of Psychosis Studies Institute of Psychiatry King s College London robin.murray@kcl.ac.uk
More informationSchizophrenia and Related Psychotic Disorders
and Related Psychotic Disorders Anand K. Pandurangi, MD Professor & Chair, Div. of Inpatient Psychiatry Director, Program VCU Medical Center 1 Kraeplin 1896 Dementia Praecox. Single, Homogenous Disorder
More informationAre they still doing that?
Are they still doing that? Why we still give ECT and when to refer Nicol Ferrier BSc (Hons), MD, FRCP(Ed), FRCPsych Emeritus Professor of Psychiatry Newcastle University Rates of prescribing ECT in the
More informationScientific Rationale for Drugs Enhancing Psychosocial Treatments. Donald C. Goff, MD Nathan Kline Institute NYU Medical School
Scientific Rationale for Drugs Enhancing Psychosocial Treatments Donald C. Goff, MD Nathan Kline Institute NYU Medical School Conflicts over the past 3 years Consultation: Eli Lilly, Bristol-Meyer-Squibb,
More informationC. Brock Kirwan, Ph.D.
, Ph.D. Department of Psychology & Neuroscience Center Brigham Young University 1052 Kimball Tower Provo, UT 84602 Phone: (801) 422-2532 kirwan@byu.edu ACADEMIC & RESEARCH POSITIONS Assistant Professor:
More informationTracey G. Skale, MD Chief Medical Officer Greater Cincinnati Behavioral Health
Schizophrenia: What Do We Know? Where Do We Go From Here? Tracey G. Skale, MD Chief Medical Officer Greater Cincinnati Behavioral Health Objectives Participants will be able to: Understand the clinical
More informationLong-term associations between use of antipsychotic medication and brain structural changes in schizophrenia
Long-term associations between use of antipsychotic medication and brain structural changes in schizophrenia a systematic review and a meta-analysis Jouko Miettunen Center for Life Course Epidemiology
More informationAdvisory Boards -- Dainippon Sumito Pharma; Takeda and Lundbeck. Off-label data included for Mirapex (pramipexole)
Disclosures Advisory Boards -- Dainippon Sumito Pharma; Takeda and Lundbeck Off-label data included for Mirapex (pramipexole) Funding from NIMH; Stanley Medical Research Institute; NARSAD A Brief History
More informationHandout for the Neuroscience Education Institute (NEI) online activity: Cognitive Impairment in Schizophrenia: The Great Unmet Need
Handout for the Neuroscience Education Institute (NEI) online activity: Cognitive Impairment in Schizophrenia: The Great Unmet Need Learning Objectives Assess and monitor cognitive impairment in patients
More informationRichard C. Gershon, PhD.
Richard C. Gershon, PhD. gershon@northwestern.edu www.healthmeasures.net Collectively PROMIS and the NIH Toolbox consist of over 250 measures. This particular presentation is limited to describing the
More informationMental Health Disorders Civil Commitment UNC School of Government
Mental Health Disorders 2017 Civil Commitment UNC School of Government Edward Poa, MD, FAPA Chief of Inpatient Services, The Menninger Clinic Associate Professor, Baylor College of Medicine NC statutes
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com Glenn Michael Dempsey, M.D. Albuquerque
More informationComputerised Assessment of Visuo-spatial Cognition in Schizophrenia An Exploratory Meta-analysis of CANTAB Findings
Computerised Assessment of Visuo-spatial Cognition in Schizophrenia An Exploratory Meta-analysis of CANTAB Findings a report by Emmanuel Stip, 1,2 Laurent Lecardeur 2 and Amir Ali Sepehry 1 1. University
More informationComplexity Made Simple
Complexity Made Simple Bussey-Saksida Touch Screen Chambers for Rats and Mice Tasks translate directly to well established monkey and human touch models e.g. CANTAB High throughput screening of multiple
More informationAfter the Diagnosis: Rehabilitation & Support Options for Mild Dementia
After the Diagnosis: Rehabilitation & Support Options for Mild Dementia Dr. Toni Nicholls, Clinical Neuropsychologist Peronne Village, cottage #20, Worthing, Christ Church 621-2022 Say these aloud Dog
More informationDiabetes and Cognition
Diabetes and Cognition Disorder-specific impairments and treatment-induced effects on cognitive function Overview Individuals with diabetes mellitus experience cognitive impairments, particularly in domains
More informationNeural Communication. Central Nervous System Peripheral Nervous System. Communication in the Nervous System. 4 Common Components of a Neuron
Neural Communication Overview of CNS / PNS Electrical Signaling Chemical Signaling Central Nervous System Peripheral Nervous System Somatic = sensory & motor Autonomic = arousal state Parasympathetic =
More informationSchizophrenia: Uncovering a molecular origin so humanity may better deal with insanity
Schizophrenia: Uncovering a molecular origin so humanity may better deal with insanity : What is Schizophrenia? Literally split mind A mental disorder comprising most major psychotic disorders; characterized
More informationThe value of the CANTAB battery in evaluating
The value of the CANTAB battery in evaluating cognitive disorders in epileptic patients Abstract Epileptic process generate, depends on the cerebral region affected, a variety of neurological impairements,
More informationRealising the potential of MILK PHOSPHOLIPIDS as an ingredient to improve cognitive function
Realising the potential of MILK PHOSPHOLIPIDS as an ingredient to improve cognitive function Professor Louise Dye Human Appetite Research Unit, Institute of Psychological Sciences Leeds University NUTRITION
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Glenn Michael Dempsey,
More informationEBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationNeuropsychological Evaluations of Capacity STEVEN E. ROTHKE, PH.D., ABPP HAYLEY AMSBAUGH, M.S.
Neuropsychological Evaluations of Capacity STEVEN E. ROTHKE, PH.D., ABPP HAYLEY AMSBAUGH, M.S. Qualifications of Neuropsychologists Doctoral degree in psychology from an accredited university training
More informationCurriculum Vitae, Corinna Alisangco Gamez, M.D. Corinna Alisangco Gamez, M.D. Pacific Research Partners, LLC. 901 Clay Street Oakland, CA 94607
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationTHE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME
PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence
More informationThe Nervous System. Biological School. Neuroanatomy. How does a Neuron fire? Acetylcholine (ACH) TYPES OF NEUROTRANSMITTERS
Biological School The Nervous System It is all about the body!!!! It starts with an individual nerve cell called a NEURON. Synapse Neuroanatomy Neurotransmitters (chemicals held in terminal buttons that
More informationIssues of Neuropsychological Assessment in International Settings
Issues of Neuropsychological Assessment in International Settings Kevin Robertson, Ph.D. Director of Neuropsychology, Neurology University of North Carolina at Chapel Hill Igor Grant, M.D. Director, HIV
More informationTropisetron: A promising drug to prevent Alzheimer s disease
Expert Opinion on Therapeutic Targets (Editorial) Tropisetron: A promising drug to prevent Alzheimer s disease Short title: Tropisetron for Alzheimer s disease Word count of the manuscript: 1324 words
More informationChapter 12. Schizophrenia and Other Psychotic Disorders. PSY 440: Abnormal Psychology. Rick Grieve Western Kentucky University
Chapter 12 Schizophrenia and Other Psychotic Disorders PSY 440: Abnormal Psychology Rick Grieve Western Kentucky University psychotic disorders disorders so severe that the person has essentially lost
More informationBrian A. Coffman, PhD
Brian A. Coffman, PhD Research Instructor Department of Psychiatry University of Pittsburgh School of Medicine UPMC Western Psychiatric Hospital Pittsburgh, PA Dr. Brian Coffman is a Research Instructor
More information10/24/2017. Medial Temporal Lobes. Autobiographical Memory. Episodic and Semantic Memory. Arlo Clark-Foos, Ph.D.
Medial Temporal Lobes Henry Molaison (HM) (1926-2008) Arlo Clark-Foos, Ph.D. Consequences of bilateral removal Episodic and Semantic Memory Endel Tulving on Declarative (Explicit) Memories Autobiographical
More informationArlo Clark-Foos, Ph.D.
Arlo Clark-Foos, Ph.D. Medial Temporal Lobes Henry Molaison (HM) (1926-2008) Consequences of bilateral removal Episodic and Semantic Memory Endel Tulving on Declarative (Explicit) Memories Episodic Memory
More informationEvidence-Based Treatments and Community Resources for Persons with Memory Loss. Prevention vs. Treatment
Evidence-Based Treatments and Community Resources for Persons with Memory Loss Presented by: Sandy C. Burgener, Ph.D., R.N., FAAN Associate Professor Emerita University of Illinois College of Nursing Adjunct
More informationDriving to Distraction
Driving to Distraction New Research on the Impact of ADHD and ADHD Medications on Driving performance Daniel J. Cox, Ph.D., A.B.P.P Professor, Departments of Psychiatric and Internal Medicine Director,
More informationChanges, Challenges and Solutions: Overcoming Cognitive Deficits after TBI Sarah West, Ph.D. Hollee Stamper, LCSW, CBIS
Changes, Challenges and Solutions: Overcoming Cognitive Deficits after TBI Sarah West, Ph.D. Hollee Stamper, LCSW, CBIS Learning Objectives 1. Be able to describe the characteristics of brain injury 2.
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationUpdate on First Psychotic Episodes in Childhood and Adolescence. Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University
Update on First Psychotic Episodes in Childhood and Adolescence Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University Childhood-Onset Psychosis 8% of psychiatrically referred youth
More informationPathology of Visual Memory in Patients with Epilepsy
Pathology of Visual Memory in Patients with Epilepsy Reza Pourhosein 1, Roghaye Moazaz 2 1 Associate Professor, Department of Psychology, School of Psychology and Education, University of Tehran, Tehran,
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationCognitive assessment in mouse models of disease
Cognitive assessment in mouse models of disease Jared W. Young, Ph.D. Department of Psychiatry, University of California, San Diego jaredyoung@ucsd.edu Schizophrenia: Genetic contribution Horrobin postulated
More informationCognitive Dysfunction Relates to Subjective Report of Mental Fatigue in Patients with Chronic Fatigue Syndrome
(2006) 31, 1777 1784 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Cognitive Dysfunction Relates to Subjective Report of Mental Fatigue in Patients
More informationImpact of Behavioral Aspects of Autism on Cognitive Abilities in Children with Autism Spectrum Disorder
Impact of Behavioral Aspects of Autism on Cognitive Abilities in Children with Autism Spectrum Disorder Rana M. Zeina, Laila AL-Ayadhi, Shahid Bashir Abstract Cognitive symptoms and behavioral symptoms
More informationUnit 3: The Biological Bases of Behaviour
Unit 3: The Biological Bases of Behaviour Section 1: Communication in the Nervous System Section 2: Organization in the Nervous System Section 3: Researching the Brain Section 4: The Brain Section 5: Cerebral
More informationCognitive Trajectories in Schizophrenia
Cognitive Trajectories in Schizophrenia Chair: Philip D. Harvey, PhD Acting Co-Chair: Kiri Granger, PhD 16 th October 2018 Cognitive Trajectories in Schizophrenia The focus of this workshop is on baseline
More informationClasses of Neurotransmitters. Neurotransmitters
1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters
More informationEFFECTS OF PHARMACOLOGICAL TREATMENTS ON COGNITION
EFFECTS OF PHARMACOLOGICAL TREATMENTS ON COGNITION Richard Keefe, PhD Professor of Psychiatry & Behavioral Sciences and Psychology & Neuroscience Duke University Medical Center Enabling Discovery, Development,
More informationKEEPING UP WITH THE CLINICAL ADVANCES: SCHIZOPHRENIA
KEEPING UP WITH THE CLINICAL ADVANCES: SCHIZOPHRENIA Learning Objectives Evaluate the potential clinical implications of evolving data on the neuropathology of schizophrenia Evaluate the mechanisms and
More informationeidisine is easily added to any food- or beverage product and gives a temporary boost of cognitive functions, including memory
eidisine TM is a natural healthy active food ingredient that makes you smarter eidisine is easily added to any food- or beverage product and gives a temporary boost of cognitive functions, including memory
More information